Select a Charity to donate to
Select Donation Amount
You're helping people with primary immunodeficiency!
You are now leaving an Octapharma property. Links to all outside sites are provided as a resource to our visitors. Octapharma disclaims any and all liability for the content, services, or privacy practices of sites that are not owned and operated by Octapharma. Linking to this site is done at your own risk.
To return to the prior page, close this window or select cancel.
To continue to the offsite link, please select continue.
Donation points are points you collect for participating in IgCares activities labeled with the donation point icon. While the points do not have cash value themselves, they represent the money we will donate to the participating PI charity you select. Every point you earn is a dollar we will donate.
Points have no cash value to IgCares program members and cannot be redeemed for any purpose other than donation through the IgCares program. One donation point = one dollar ($1.00).
Yes. All donation points must be donated by IgCares program members during the current 12-month calendar period. Donation points collected but not donated by a member during that 12-month calendar period will expire and no longer be valid for donation.
Go to the Give page. how many points you have to donate, then select the amount of points you want to donate and the IgCares program charity to receive them. That’s all it takes!
We will email you once this event has been scheduled so that you can sign up.
Check your email for event confirmation and participation details from Zoom. You should receive the email within about five minutes. The email will be sent to you by firstname.lastname@example.org. If you do not see the confirmation email in your inbox, please check your Spam folder, and if the email is there, mark it as ”not spam” and add email@example.com to your Address Book. If you can’t locate the email at all, please contact the IgCares Support Center at 1-833-382-7686.
*All fields required unless indicated otherwise
Indications and Important Safety Information for cutaquig® (Immune Globulin Subcutaneous [Human]– hipp, 16.5% solution)
See the cutaquig full prescribing information for complete boxed warning
Thrombosis may occur with immune globulin products, including cutaquig.
Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors.
For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Indications and Usage
Cutaquig® (Immune Globulin Subcutaneous (Human)-hipp) is a 16.5% immune globulin solution for subcutaneous infusion (IGSC), indicated as replacement therapy for primary humoral immunodeficiency (PI) in adults and pediatric patients 2 years of age and older. This includes, but is not limited to, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, congenital agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiencies.
IMPORTANT SAFETY INFORMATION
Cutaquig is contraindicated in patients who have had an anaphylactic or severe systemic reaction to the subcutaneous administration of human immune globulin or to any of the components of cutaquig such as Polysorbate 80, and in IgA-deficient patients with antibodies against IgA and a history of hypersensitivity.
Warnings and Precautions
Severe hypersensitivity reactions may occur with cutaquig, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the cutaquig infusion immediately and initiate appropriate treatment. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions.
Thrombosis may occur following treatment with immune globulin products, including cutaquig. For patients at risk of thrombosis, administer cutaquig at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.
Falsely elevated blood glucose readings may occur during and after the infusion of cutaquig with some glucometer and test strip systems. When administering cutaquig, measure blood glucose with a glucose-specific method.
Aseptic meningitis syndrome (AMS) can occur with cutaquig. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously and may occur within 2 days following treatment. Discontinuation of immunoglobulin treatment has resulted in remission within several days without sequelae.
Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin, especially those containing sucrose. cutaquig does not contain sucrose. Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure.
Monitor cutaquig recipients for clinical signs and symptoms of hemolysis, particularly patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after cutaquig infusion.
Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. Monitor for pulmonary adverse reactions (transfusion-related acute lung injury, TRALI). If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support.
Cutaquig is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent.
After infusion of cutaquig, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological test results, with the potential for misleading interpretation.
The most common adverse reactions (≥ 5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough.
Please see the cutaquig full prescribing information